Two former LCRF grantees and a Scientific Advisory Board (SAB) member were among the co-authors of a study, “Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer,” published recently in Nature Cancer.
![](https://www.lungcancerresearchfoundation.org/wp-content/uploads/IDJ.jpg)
![](https://www.lungcancerresearchfoundation.org/wp-content/uploads/Aaron-Hata-edited.jpg)
![Satoshi Yoda](https://www.lungcancerresearchfoundation.org/wp-content/uploads/SatoshiYoda-edited.jpg)
Satoshi Yoda, PhD, and Aaron Hata, MD, PhD both received grants from LCRF, and Ibiayi Dagogo-Jack, MD, was recently named as a member of LCRF’s SAB.